BrYet

Executive Summary

BrYet is a privately-held, preclinical biotechnology company headquartered in Cambridge, MA with operations in Houston, TX. Founded in 2021, the company is pioneering a novel class of multi-component therapeutics designed to target cancer-specific molecular transport phenotypes, aiming to cure advanced and metastatic cancers, with an initial focus on primary and metastatic lung and liver malignancies. By exploiting unique transport mechanisms on cancer cells, BrYet's approach seeks to enhance drug delivery specifically to tumors, potentially overcoming key limitations of conventional therapies such as poor penetration and resistance. The company's platform is in the preclinical stage, and no funding or valuation data are publicly disclosed. BrYet represents an early-stage opportunity in the targeted drug delivery space, with a strategy centered on first-in-class mechanisms for hard-to-treat cancers.

Upcoming Catalysts (preview)

• Q4 2026Preclinical Proof-of-Concept Data in Liver Cancer Models40% success
• H1 2027Series A Financing Round60% success
• 2027Partnership or Licensing Deal with Larger Pharma30% success